Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1078-1087

  Goetz, Matthew P ^a   Toft, David ^a   Reid, Joel ^a   Ames, Matthew ^a   Stensgard, Bridget ^a   Safgren, Stephanie ^a   Adjei, Araba A ^a   Sloan, Jeff ^a   Atherton, Pamela ^a   Vasile, Vlad ^a   Salazaar, Sandra ^a   Adjei, Alex ^a   Croghan, Gary ^a   Erlichman, Charles ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHAPERONE; CYTOCHROME P450; CYTOCHROME P450 3A5; HEAT SHOCK PROTEIN 70; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; CYP3A PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; DRUG DERIVATIVE; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; NQO1 PROTEIN, HUMAN; RIFABUTIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME POLYMORPHISM; FATIGUE; FEMALE; GENOTYPE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETICS; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; POLYMORPHISM, GENETIC; RIFABUTIN;

EID: 20044384168     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.119     Document Type: Article

References (36)

1. Morimoto RI, Kline MP, Bimston DN, et al: The heat-shock response: Regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 32:17-29, 1997
2. Hartl FU, Hayer-Hartl M: Molecular chaperones in the cytosol: From nascent chain to folded protein. Science 295:1852-1858, 2002
3. Young JC, Moarefi I, Hartl FU: Hsp90: A specialized but essential protein-folding tool. J Cell Biol 154:267-273, 2001
4. Pratt WB, Toft DO: Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360, 1997
5. Richter K, Buchner J: Hsp90: Chaperoning signal transduction. J Cell Physiol 188:281-290, 2001
6. Whitesell L, Mimnaugh EG, De Costa B, et al: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324-8328, 1994
7. Goetz MP, Toft DO, Ames MM, et al: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14:1169-1176, 2003
8. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61, 2002
9. Workman P: Overview: Translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 3:297-300, 2003
10. Whitesell L, Bagatell R, Falsey R: The stress response: Implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 3:349-358, 2003
11. Supko JG, Hickman RL, Grever MR, et al: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315, 1995
12. Kelland LR, Sharp SY, Rogers PM, et al: DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949, 1999
13. Burger AM, Fiebig HH, Stinson SF, et al: 17-(Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377-387, 2004
14. Bagatell R, Khan O, Paine-Murrieta G, et al: Destabilization of steroid receptors by heat shock protein 90-binding drugs: A ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7:2076-2084, 2001
15. Nguyen DM, Lorang D, Chen GA, et al: Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: In vitro and in vivo analysis. Ann Thorac Surg 72:371-378, 2001
16. Yang J, Yang JM, Iannone M, et al: Disruption of the EF-2 kinase/Hsp90 protein complex: A possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res 61:4010-4016, 2001
17. Egorin MJ, Zuhowski EG, Rosen DM, et al: Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47:291-302, 2001
18. Egorin MJ, Rosen DM, Wolff JH, et al: Metabolism of 17-(allylamino)-17- demethoxy-geldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385-2396, 1998
19. Hustert E, Haberl M, Burk O, et al: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779, 2001
20. Gaedigk A, Tyndale RF, Jurima-Romet M, et al: NAD(P)H: quinone oxidoreductase: Polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 8:305-313, 1998
21. Johnson JL, Toft DO: Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol 9:670-678, 1995
22. Barent RL, Nair SC, Carr DC, et al: Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol Endocrinol 12:342-354, 1998
23. Smith DF, Sullivan WP, Marion TN, et al: Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70. Mol Cell Biol 13:869-876, 1993
24. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
25. Gelmon KA, Eisenhauer EA, Harris AL, et al: Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development? J Natl Cancer Inst 91:1281-1287, 1999
26. Sausville EA, Tomaszewski JE, Ivy P: Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 3:377-383, 2003
27. Xu L, Eiseman JL, Egorin MJ, et al: Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 30:185-219, 2003
28. Lawson B, Brewer JW, Hendershot LM: Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway. J Cell Physiol 174:170-178, 1998
29. Hegde RS, Zuo J, Voellmy R, et al: Short circuiting stress protein expression via a tyrosine kinase inhibitor, herbimycin A. J Cell Physiol 165:186-200, 1995
30. Murakami Y, Uehara Y, Yamamoto C, et al: Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes. Exp Cell Res 195:338-344, 1991
31. Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al: Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 93:14536-14541, 1996
32. Kamal A, Thao L, Sensintaffar J, et al: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410, 2003
33. Zhang HJ, Chung D, Yong-Ching Y, et al: Identification of new biomarkers for clinical trials of hsp90 inhibitors. Proc Am Assoc Cancer Res 45:894, 2004 (abstr 3877)
34. Kuehl P, Zhang J, Lin Y, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391, 2001
35. Schnur RC, Corman ML, Gallaschun RJ, et al: Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38:3806-3812, 1995
36. Munster PN, Basso A, Solit D, et al: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin Cancer Res 7:2155-2158, 2001. Clin Cancer Res 7:2228-2236, 2001